

Contents

Targeting Type 2 Diabetes	1
Christina Schwanstecher and Mathias Schwanstecher	
Dual Acting and Pan-PPAR Activators as Potential Anti-diabetic Therapies	35
Monique Heald and Michael A. Cawthorne	
GLP-1 Agonists and Dipeptidyl-Peptidase IV Inhibitors	53
Baptist Gallwitz	
Cannabinoids and Endocannabinoids in Metabolic Disorders with Focus on Diabetes	75
Vincenzo Di Marzo, Fabiana Piscitelli, and Raphael Mechoulam	
SGLT Inhibitors as New Therapeutic Tools in the Treatment of Diabetes	105
Rolf K.H. Kinne and Francisco Castaneda	
Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 in Antidiabetic Therapy	127
Minghan Wang	
Nampt and Its Potential Role in Inflammation and Type 2 Diabetes	147
Antje Garten, Stefanie Petzold, Susanne Schuster, Antje Körner, Jürgen Kratzsch, and Wieland Kiess	
Inhibition of Ganglioside Biosynthesis as a Novel Therapeutic Approach in Insulin Resistance	165
Jin-ichi Inokuchi	

Overcoming Insulin Resistance with Ciliary Neurotrophic Factor 179
Tamara L. Allen, Vance B. Matthews, and Mark A. Febbraio

**Thermogenesis and Related Metabolic Targets
in Anti-Diabetic Therapy** 201
Jonathan R.S. Arch

**Interleukin-Targeted Therapy for Metabolic Syndrome
and Type 2 Diabetes** 257
Kathrin Maedler, Gitanjali Dharmadhikari, Desiree M. Schumann,
and Joachim Størling

**Fructose-1, 6-Bisphosphatase Inhibitors for Reducing
Excessive Endogenous Glucose Production in Type 2 Diabetes** 279
Paul D. van Poelje, Scott C. Potter, and Mark D. Erion

AMP-Activated Protein Kinase and Metabolic Control 303
Benoit Viollet and Fabrizio Andreelli

Mitochondria as Potential Targets in Antidiabetic Therapy 331
Paula I. Moreira and Catarina R. Oliveira

**Research and Development of Glucokinase Activators
for Diabetes Therapy: Theoretical and Practical Aspects** 357
Franz M. Matschinsky, Bogumil Zelent, Nicolai M. Doliba,
Klaus H. Kaestner, Jane M. Vanderkooi, Joseph Grimsby,
Steven J. Berthel, and Ramakanth Sarabu

Index 403